Fig. 7.
Treatment of aggressive minimal and advanced Daudi lymphoma disease with LL2-onconase or component proteins.
Daudi lymphoma cells (5 × 106 cells) were injected iv, followed 1 or 7 days later with daily iv injections for 5 consecutive days of PBS (open triangles), 80 μg LL2 + 20 μg onconase (open circles and squares, treatment days 1 to 5 and 7 to 11, respectively), or 100 μg LL2-onconase (solid circles and squares, treatment days 1 to 5 and 7 to 11, respectively) as described in “Materials and methods.” Both groups of mice treated with LL2-onconase survived significantly longer than PBS (P < .0001) or a mixture of LL2 plus onconase (P < .0002) treated mice.
